By Fineline Cube 
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual results, achieving a revenue of RMB 1.098 billion, marking a 48.02% year-on-year (YOY) increase. The net loss attributable to the parent company narrowed by 42.40% YOY to RMB 450 million.
Revenue Drivers
The growth was primarily driven by increased sales of telitacicept (RC18), a dual-target fusion protein for moderate-to-severe systemic lupus erythematosus (SLE) and rheumatoid arthritis, and disitamab vedotin (RC48), a HER2 antibody-drug conjugate (ADC) for urothelial carcinoma and gastric cancer. In May 2025, telitacicept received additional approval for adult generalized myasthenia gravis, while disitamab vedotin was approved for advanced breast cancer with HER2-positive status and liver metastases. An additional application for HER2-low expressing breast cancer was also submitted to the NMPA.
Commercialization Teams
As of June 30, 2025, RemeGen’s autoimmune commercialization team had approximately 900 sales personnel, and its oncology team exceeded 500 members. Both teams completed drug access in over 1,000 hospitals.-Fineline Info & Tech